2007
December 6th
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

July 30th
TargeGen Initiates Multi-Center Phase II Clinical Trial of TG100801, A Topically Applied Kinase Inhibitor In Macular Degeneration

July 12th
TargeGen, Inc. Closes $40M Series "D" Financing Round

June 7th
FierceBiotech Names TargeGen as One of the “Fierce 15" Biotech Companies of 2007

May 9th
TargeGen Receives 2007 James D. Watson Helix Award In The Private Company Category

March 12th
TargeGen, Inc., Appoints Martin Friedlander, M.D., Ph.D. To Scientific Advisory Board

February 27th
TargeGen Announces Successful Completion of Phase I Clinical Trial Of Topical AMD Drug TG100801

January 5th
TargeGen Selects Jak2 Inhibitor Lead (TG101348) for Clinical Development as a Potential Therapy for Myeloproliferative Diseases Including Polycythemia Vera (PV)

2006
November 1st
TargeGen Initiates Phase I Clinical Trial Of Topical AMD Drug TG100801

October 16th
TargeGen Receives USPTO Notice Of Allowance For U.S. Patent Application 10/679,209 Pertaining To TG100-115 And Related Compounds

June 29th
FDA Grants Fast Track Designation For TargeGen TG100-115 Cardiovascular Compound

June 15th
TargeGen CEO Peter Ulrich Receives 2006 Ernst & Young Entrepreneur of the Year Award

April 4th
TargeGen Presents Data For TG100801, A Topically Applied Compound For The Potential Treatment Of Major Eye Diseases Including Macular Degeneration

2005
December 8th
TargeGen Announces Planned Relocation of Company Operations in January 2006 and Expansion of Internal Capabilities

August 31st
TargeGen, Inc. Closes $30M Series “C” Preferred Venture Financing Round

July 28th
TargeGen, Inc. Selects Lead Drug for Clinical Development As A Topical (Eyedrop) Treatment For Wet Macular Degeneration and Other Eye Diseases

May 13th
TargeGen, Inc. Appoints Phillip M. Schneider To Board of Directors

January 4th
TargeGen Initiates Phase I/II Clinical Trial Of TG100-115 In Heart Attack Patients – First Patient Treated

2004
December 2nd
TargeGen TG100-115 Wins UCSD CONNECT 2004 Most Innovative Product Award In Biotechnology R&D Category

October 19th
TargeGen TG100-115 Is Named One Of Three Finalists For UCSD CONNECT 2004 Most Innovative Product Award In Biotechnology R&D Category

July 19th
TargeGen Plans Near Term Initiation Of Phase I/II Clinical Trial Of TG100-115 In Heart Attack Patients Under The Company’s First Active IND

June 30th
TargeGen, Inc. Selects Lead Drug for Clinical Development in Oncology and Edema Indications

June 30th
Cydex, Inc. Licenses Captisol® To Targegen, Inc. For Cardiovascular Drug Candidate And Future Pipeline

June 25th
TargeGen, Inc. Appoints Sara A. Courtneidge, Ph.D. To Scientific Advisory Board

January 13th
TargeGen, Inc. Concludes Successful $30M Second Round Of Financing

For archived news stories, click here.